Free Trial

Monte Rosa Therapeutics (GLUE) Earnings Date, Estimates & Call Transcripts

Monte Rosa Therapeutics logo
$19.35 -0.22 (-1.12%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$19.89 +0.54 (+2.79%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Monte Rosa Therapeutics Earnings Summary

Monte Rosa Therapeutics released Q4 2025 earnings on March 17, 2026, reporting an EPS of -$0.55, which missed analysts' consensus estimates of -$0.45 by $0.10. Quarterly revenue was reported to be $2.78 million, below the consensus estimate of $17.09 million. With a trailing EPS of -$0.46, Monte Rosa Therapeutics' earnings are expected to decrease next year, from ($1.13) to ($1.19) per share.

Upcoming
Earnings Date
May. 7Before Market OpensEstimated
Consensus EPS
(Mar. 17)
-$0.45
Actual EPS
(Mar. 17)
-$0.55 Missed By -$0.10
Actual Revenue
(Mar. 17)
$2.78M

Q4 2025 Earnings Resources

GLUE Upcoming Earnings

Monte Rosa Therapeutics' Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules

Get Monte Rosa Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

GLUE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GLUE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Monte Rosa Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.36-$0.36-$0.36
Q2 20261-$0.31-$0.31-$0.31
Q3 20261-$0.29-$0.29-$0.29
Q4 20261-$0.31-$0.31-$0.31

Monte Rosa Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/7/2026
(Estimated)
--------
3/17/2026Q4 2025-$0.45-$0.55 -$0.10-$0.55$17.09M$2.78M
11/6/2025Q3 2025-$0.39-$0.33+$0.06-$0.33$7.37M$12.77M
8/7/2025Q2 2025-$0.31-$0.15+$0.16-$0.15$7.23M$23.19M
5/8/2025Q1 2025-$0.24$0.57+$0.81$0.57$13.57M$84.93M
3/20/2025Q4 2024-$0.37$0.23+$0.60$0.23$43.73M$14.00M
11/7/2024Q3 2024-$0.45-$0.29+$0.16-$0.29$4.54M$9.22M
8/8/2024--$0.50-$0.43+$0.07-$0.43$3.20M$4.70M
5/9/2024Q1 2024-$0.56-$0.53+$0.03-$0.53$4.29M$1.06M

Data powered by Fiscal.ai.

Monte Rosa Therapeutics Earnings - Frequently Asked Questions

Monte Rosa Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 7th, 2026 based off last year's report dates. Learn more on GLUE's earnings history.

In the previous quarter, Monte Rosa Therapeutics (NASDAQ:GLUE) missed the analysts' consensus estimate of ($0.45) by $0.10 with a reported earnings per share (EPS) of ($0.55). Learn more on analysts' earnings estimate vs. GLUE's actual earnings.

Monte Rosa Therapeutics (NASDAQ:GLUE) has a recorded annual revenue of $123.67 million.

Monte Rosa Therapeutics (NASDAQ:GLUE) has a recorded net income of -$38.63 million. GLUE has generated -$0.46 earnings per share over the last four quarters.

Monte Rosa Therapeutics' earnings are expected to decrease from ($1.13) per share to ($1.19) per share in the next year.


This page (NASDAQ:GLUE) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners